Nock et al., 2023 - Google Patents
Barriers, perceived benefits and preferences to exercise in adults with an opioid use disorder in the USNock et al., 2023
View HTML- Document ID
- 2463559809398609663
- Author
- Nock N
- Hernandez E
- Robinson D
- Hoffer L
- Wachholtz A
- Publication year
- Publication venue
- Preventive Medicine Reports
External Links
Snippet
Abstract Introduction Over 10 million Americans misuse opioids and more than 5 million have been diagnosed with an opioid use disorder (OUD). In 2021, over 100,000 Americans died of a drug overdose and more than 75% of these deaths involved an opioid. Exercise …
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bender et al. | Assessing the risk–benefit profile of classical psychedelics: A clinical review of second-wave psychedelic research | |
| Winkelman | Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, Peyote, Ibogaine and Ayahuasca | |
| Hall et al. | Extended treatment of older cigarette smokers | |
| da Costa et al. | Stopping smoking: a prospective, randomized, double-blind study comparing nortriptyline to placebo | |
| Sumnall et al. | Use, function, and subjective experiences of gamma-hydroxybutyrate (GHB) | |
| Althof | What’s new in sex therapy (CME) | |
| WO2018195455A1 (en) | Assessing and treating psychedelic-responsive subjects | |
| Roll | Contingency management: an evidence‐based component of methamphetamine use disorder treatments | |
| Sullivan et al. | Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin | |
| Boddi et al. | An integrated approach with vardenafil orodispersible tablet and cognitive behavioral sex therapy for treatment of erectile dysfunction: a randomized controlled pilot study | |
| Hall et al. | Using extended cognitive behavioral treatment and medication to treat dependent smokers | |
| Merlin et al. | Pain self-management in HIV-infected individuals with chronic pain: a qualitative study | |
| Kapitány‐Fövény et al. | Enhancing sexual desire and experience: an investigation of the sexual correlates of gamma‐hydroxybutyrate (GHB) use | |
| Culbertson et al. | Virtual reality cue exposure therapy for the treatment of tobacco dependence | |
| Nock et al. | Barriers, perceived benefits and preferences to exercise in adults with an opioid use disorder in the US | |
| Begola et al. | Hallucinogens and their therapeutic use: A literature review | |
| Parrott et al. | MDMA and methamphetamine: some paradoxical negative and positive mood changes in an acute dose laboratory study | |
| Foltin et al. | Intranasal cocaine in humans: acute tolerance, cardiovascular and subjective effects | |
| LaGrotta | Gender differences in addiction | |
| Chen et al. | The effects of exercise with nicotine replacement therapy for smoking cessation in adults: A systematic review | |
| Stotts et al. | Using acceptance and commitment therapy during methadone dose reduction: Rationale, treatment description, and a case report | |
| Wilbourne et al. | Treatment for alcoholism: Older and wiser? | |
| Gómez-Busto et al. | Virtual reality and psychedelics for the treatment of psychiatric disease: a systematic literature review | |
| Oncken et al. | Transdermal nicotine for smoking cessation in postmenopausal women | |
| Kouri et al. | Nicotine alters some of cocaine's subjective effects in the absence of physiological or pharmacokinetic changes |